Dan joined Samsara BioCapital as a Venture Partner in 2023. He works with our portfolio companies on financial strategy, planning, and execution as well as IPO readiness and finance team development. Mr. Spiegelman has over 30 years of executive finance experience at biotech companies, having served as CFO at BioMarin Pharmaceutical, CFO at CV Therapeutics and Treasurer at Genentech Inc. Mr. Spiegelman currently serves as Board Chairman for Tizona Therapeutics, and Audit Committee Chairman for Myriad Genetics (NASDAQ: MYRD), Spruce Biosciences (NASDAQ: SPRB), Opthea Limited (NASDAQ: OPTH), Maze Therapeutics and Kyverna Therapeutics, and has previously served as board director for several other companies. During his career as a financial executive and board director he has raised over $5B through financing transactions that have included IPO’s, follow-ons, reverse mergers, convertible debt, bank debt and equity lines of credit. Mr. Spiegelman has both buy side and sell side M&A experience, with several billion-dollar plus transactions. Mr. Spiegelman has also co-founded companies, including Rapidscan Pharma Solutions which was sold to GE Healthcare.
Mr. Spiegelman received a Bachelor of Arts degree from Stanford University and an MBA from the Stanford Graduate School of Business.